Hypercalcemia and cancer: Differential diagnosis and treatment.
TLDR
The initial workup, differential diagnoses, confirmatory laboratory testing, imaging, and medical and surgical management of hypercalcemia are described in the patient with cancer.Abstract:
Incidentally detected hypercalcemia usually presents in an indolent manner and is most likely caused by primary hyperparathyroidism. In contrast, hypercalcemia in the patient with a history of cancer presents in a wide range of clinical settings and may be severe enough to warrant hospitalization. This form of hypercalcemia is usually secondary to hypercalcemia of malignancy and can be fatal. Hypercalcemia of malignancy is most commonly mediated by tumoral production of parathyroid hormone-related protein or by cytokines activating osteoclast degradation of bone. The initial workup, differential diagnoses, confirmatory laboratory testing, imaging, and medical and surgical management of hypercalcemia are described in the patient with cancer.read more
Citations
More filters
Journal ArticleDOI
Parathyroid Surgery: What Radiologists Need to Know.
TL;DR: A combination of patient clinical history and radiographic imaging is used to determine the most appropriate surgical strategy for hyperparathyroidectomy or bilateral cervical exploration as discussed by the authors, which provides high rates of cure with low rates of persistence or recurrence.
Journal ArticleDOI
An Atypical Presentation of Primary Hyperparathyroidism in an Adolescent: A Case Report of Hypercalcaemia and Neuropsychiatric Symptoms Due to a Mediastinal Parathyroid Adenoma
Roberta Minelli,Aniello Meoli,Alessandra Tiri,Umberto Fanelli,Rosanna Iannarella,Pierpacifico Gismondi,Susanna Esposito +6 more
TL;DR: The case of a 17-year-old girl affected by anorexia nervosa, depression and self-harm with incidental detection of moderate hypercalcaemia is described, demonstrating that serum calcium concentration should be evaluated in adolescents with neurobehavioural symptoms and in cases of hyperCalcaemia PHPT should be excluded.
Journal ArticleDOI
Parathyroid Hormone Secretion and Related Syndromes
Ketaki Dawale,A.K. Agrawal +1 more
TL;DR: In this article , the parathyroid gland and its anatomy, physiology, and pathology are discussed and a brief discussion about its secretion and also about various clinical syndromes related to it.
Journal ArticleDOI
Ectopic parathyroid hormone as a rare aetiology of hypercalcemia with rhabdomyosarcoma: a new treatment strategy with zoledronic acid and Denosumab
TL;DR: In this paper , a case of rhabdomyosarcoma accompanied by hypercalcemia of malignancy (HCM) and ectopic parathyroid hormone (PTH) secretion was reported.
References
More filters
Journal ArticleDOI
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
David E. Hughes,Kenneth R. Wright,Harry L. Uy,Harry L. Uy,Akira Sasaki,Toshiyuki Yoneda,David G. Roodman,David G. Roodman,Gregory R. Mundy,Brendan F. Boyce +9 more
TL;DR: Osteoclast apoptosis may be a major mechanism whereby bisphosphonates reduce osteoclast numbers and activity, and induction of apoptosis could be a therapeutic goal for new antiosteoclast drugs.
Journal ArticleDOI
Clinical practice. Hypercalcemia associated with cancer.
TL;DR: A 47-year-old woman with a history of breast cancer presents with confusion and dehydration and bone scintigraphy reveals no evidence of skeletal involvement by the tumor.
Journal ArticleDOI
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials
Pierre Major,Alain Lortholary,J. Hon,E Abdi,Gordon B. Mills,H D Menssen,F Yunus,Richard Bell,Jean-Jacques Body,E Quebe-Fehling,John W. Seaman +10 more
TL;DR: Zoledronic acid is superior to pamidronate; 4 mg is the dose recommended for initial treatment of HCM and 8 mg for relapsed or refractory hypercalcemia.
Journal ArticleDOI
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
Fred Saad,Janet E. Brown,C. Van Poznak,Toni Ibrahim,Salomon M. Stemmer,Alison Stopeck,Ingo Diel,Shunji Takahashi,Neal D. Shore,David H. Henry,Carlos H. Barrios,T. Facon,Francis M. Senecal,Karim Fizazi,Lei Zhou,Alan H. Daniels,P. Carriere,Roger Dansey +17 more
TL;DR: In this combined analysis of three prospective trials, Osteonecrosis of the jaw was infrequent, management was mostly conservative, and healing occurred in over one-third of the patients.
Journal ArticleDOI
Denosumab and bisphosphonates: different mechanisms of action and effects.
TL;DR: It is suggested that the key pharmacological differences between denosumab and the bisphosphonates reside in the distribution of the drugs within bone and their effects on precursors and mature osteoclasts, which may explain differences in the degree and rapidity of reduction of bone resorption, their potential differential effects on trabecular and cortical bone, and the reversibility of their actions.